Section Arrow
ACRS.NASDAQ
- Aclaris Therapeutics
Quotes are at least 15-min delayed:2025/12/20 17:12 EST
Regular Hours
Last
 3.14
+0.06 (+1.95%)
Day High 
3.23 
Prev. Close
3.08 
1-M High
3.475 
Volume 
2.47M 
Bid
3.05
Ask
3.12
Day Low
3.05 
Open
3.09 
1-M Low
2.342 
Market Cap 
333.70M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.18 
20-SMA 2.95 
50-SMA 2.53 
52-W High 3.475 
52-W Low 1.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.58/-0.53
Enterprise Value
344.36M
Balance Sheet
Book Value Per Share
1.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.72M
Operating Revenue Per Share
0.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.18+3.29+30.21%-- 
RXRXRecursion Pharmaceuticals4.26-0.18-4.05%-- 
IBRXImmunityBio2.08-0.01-0.48%-- 
PBMPsyence Biomedical Ltd1-0.46-31.51%0.04PE
GOVXGeoVax Labs0.1592-0.0809-33.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.